462 related articles for article (PubMed ID: 24674779)
1. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
2. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
[TBL] [Abstract][Full Text] [Related]
4. Immunopathogenesis of neuromyelitis optica.
Levy M; Wildemann B; Jarius S; Orellano B; Sasidharan S; Weber MS; Stuve O
Adv Immunol; 2014; 121():213-42. PubMed ID: 24388217
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
6. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
[TBL] [Abstract][Full Text] [Related]
8. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.
Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y
Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
10. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
[TBL] [Abstract][Full Text] [Related]
11. The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
Quan C; ZhangBao J; Lu J; Zhao C; Cai T; Wang B; Yu H; Qiao J; Lu C
J Neuroimmunol; 2015 May; 282():45-53. PubMed ID: 25903728
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
13. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
[TBL] [Abstract][Full Text] [Related]
14. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica pathogenesis and aquaporin 4.
Graber DJ; Levy M; Kerr D; Wade WF
J Neuroinflammation; 2008 May; 5():22. PubMed ID: 18510734
[TBL] [Abstract][Full Text] [Related]
16. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations.
Kowarik MC; Dzieciatkowska M; Wemlinger S; Ritchie AM; Hemmer B; Owens GP; Bennett JL
J Neuroinflammation; 2015 Jan; 12():19. PubMed ID: 25626447
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
Jarius S; Wildemann B
Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
[TBL] [Abstract][Full Text] [Related]
18. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
[TBL] [Abstract][Full Text] [Related]
19. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
20. [Neuromyelitis optica: a separate disease entity associated with aquaporin-4-antibodies].
Jordan B; Eger K; Kornhuber ME; Zierz S
Fortschr Neurol Psychiatr; 2008 Jan; 76(1):21-7. PubMed ID: 18189220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]